Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2006-05-30
2006-05-30
Helms, Larry R. (Department: 1642)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C530S387100, C530S387300
Reexamination Certificate
active
07052873
ABSTRACT:
A reshaped human anti-HM1.24 antibody comprising:(A) L chains each comprising (1) a constant region of a human L chain, and (2) FRs of a human L chain, and CDRs of L chain of mouse anti-HM1.24 monoclonal antibody; and(B) H chains each comprising (2) a constant region of a human H chain, and (2) FRs of a human H chain, and CDRs of H chain of mouse anti-HM1.24 monoclonal antibody. Since the majority of the reshaped human antibody is derived from human antibody and the CDR has a low antigenicity, the reshaped human antibody of the present invention has low antigenicity and therefore is very promising in medical and therapeutic applications.
REFERENCES:
patent: WO 90/07861 (1990-07-01), None
patent: WO 91/09967 (1991-07-01), None
Rudikoff et al (Proc Natl Acad Sci USA 1982 vol. 79 p. 1979.
Tetsuya Goto et al., “A Novel Membrane Antigen Selectively Expressed on Terminally Defferentiated Human B Cells.”, Blood, vol. 84, No. 6, pp. 1922-1930, Sep. 15, 1994.
Peter T. Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse.”, Nature, vol. 321, pp. 522-525, May 29, 1986.
Catherine A. Kettleborough et al., “Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation.”, Protein Entineering, vol. 4, No. 7, pp. 773-783, 1991.
Cary Queen et al., “A humanized antibody that binds to the interleukin 2 receptor.”, Proceedings of the National Academy of Science, vol. 86, pp. 10029-10033, Dec. 1989.
Lutz Riechmann et al., “Reshaping human antibodies for therapy.”, Nature, vol. 332, pp. 323-327, Mar. 24, 1988.
Koh Sato et al., “Humanization of a Mouse Anti-Human Interleukin-6 Receptor Antibody Comparing Two Methods for Selecting Human Framework Regions.”, Molecular Immunology, vol. 31, No. 5, pp. 371-381, 1994.
Man Sung Co et al., “Humanized antibodies for antiviral therapy.”, Proceedings of the National Academy of Science, vol. 88, pp. 2869-2873, Apr. 1991.
Martine Verhoeyen et al., “Reshaping Human Antibodies: Grafting an Antilysozyme Activity.”, Science, vol. 239, pp. 1534-1536, Mar. 25, 1988.
M.A. Roguska et al., “A comparison of two murine monoclonal antibodies humanized by CDR-grafting and Variable domain resurfacing”,Protein Engineering, vol. 9, No. 10, pp. 895-904, (1996).
J.T. Pedersen et al., “Comparison of suface accessible residues in human and murine immunoglobulin Fv domains”,J. Mol. Biol., vol. 235, pp. 959-973, (1994).
M.A. Roguska et al., “Humanization of murine monoclonal antibodies through variable domain resurfacing”,Proc. Natl. Acad. Sci. USA, vol. 91, pp. 969-973, (1994).
Ohtomo, Toshihiko, et al., “Humanization of Mouse ONS-M21 Antibody with the Aid of Hybrid Variable Regions”, Molecular Immunology, vol. 32, No. 6, Apr. 1995, pp. 407-416.
Ono, Koichiro, et al., “The Humanized Anti-HMI.24 Antibody Effective Kills Multiple Myeloma Cells by Human Effector Cell-Mediated Cytotoxicity”, Molecular Immonology, vol. 36, No. 6, Apr. 1999, pp. 387-395.
Chugai Seiyaku Kabushiki Kaisha
Foley & Lardner LLP
Helms Larry R.
LandOfFree
Natural human antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Natural human antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Natural human antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3565020